Treatment of corneal neovascularization using anti-VEGF bevacizumab

Journal of Ophthalmology

Volumn 2014, Issue , 2014, Pages

  Krizova, Deli ^a   Vokrojova, Magdalena ^a   Liehneova, Katerina ^a   Studeny, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899504447     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2014/178132     Document Type: Article

References (32)

1. Arnold J., Experimentelle Untersuchungen uber die Entwicklung. Virchows Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin 1872 54 1 30
2. Azar D. T., Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American ophthalmological society thesis). Transactions of the American Ophthalmological Society 2006 104 264 302 2-s2.0-33947651126 (Pubitemid 46495064)
3. Chang J., Gabison E. E., Kato T., Azar D. T., Corneal neovascularization. Current Opinion in Ophthalmology 2001 12 4 242 249 2-s2.0-0034887136 10.1097/00055735-200108000-00002 (Pubitemid 32751680)
4. Ambati B. K., Patterson E., Jani P., Jenkins C., Higgins E., Singh N., Suthar T., Vira N., Smith K., Caldwell R., Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. The British Journal of Ophthalmology 2007 91 4 505 508 (Pubitemid 46623686)
5. Bock F., Onderka J., Dietrich T., Bachmann B., Pytowski B., Cursiefen C., Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 1 115 119 2-s2.0-36448963785 10.1007/s00417-007-0683-5 (Pubitemid 350162691)
6. Cursiefen C., Immune privilege and angiogenic privilege of the cornea. Chemical Immunology and Allergy 2007 92 50 57 2-s2.0-33947509344 10.1159/000099253 (Pubitemid 47096896)
7. Cursiefen C., Kruse F., New aspects of angiogenesis in the cornea. Essentials in Ophthalmology 2006 83 99
8. Qazi Y., Maddula S., Ambati B. K., Mediators of ocular angiogenesis. Journal of Genetics 2009 88 4 495 515 2-s2.0-77951932130 10.1007/s12041-009- 0068-0
9. Cursiefen C., Chen L., Saint-Geniez M., Hamrah P., Jin Y., Rashid S., Pytowski B., Persaud K., Wu Y., Streilein J. W., Dana R., Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proceedings of the National Academy of Sciences of the United States of America 2006 103 30 11405 11410 2-s2.0-33746621996 10.1073/pnas.0506112103 (Pubitemid 44156530)
10. Ellenberg D., Azar D. T., Hallak J. A., Tobaigy F., Han K. Y., Jain S., Zhou Z., Chang J., Novel aspects of corneal angiogenic and lymphangiogenic privilege. Progress in Retinal and Eye Research 2010 29 3 208 248 2-s2.0-77951206611 10.1016/j.preteyeres.2010.01.002
11. Ambati B. K., Nozaki M., Singh N., Takeda A., Jani P. D., Suthar T., Albuquerque R. J. C., Richter E., Sakurai E., Newcomb M. T., Kleinman M. E., Caldwell R. B., Lin Q., Ogura Y., Orecchia A., Samuelson D. A., Agnew D. W., St Leger J., Green W. R., Mahasreshti P. J., Curiel D. T., Kwan D., Marsh H., Ikeda S., Leiper L. J., Collinson J. M., Bogdanovich S., Khurana T. S., Shibuya M., Baldwin M. E., Ferrara N., Gerber H., de Falco S., Witta J., Baffi J. Z., Raisler B. J., Ambati J., Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006 443 7114 993 997 2-s2.0-33750430869 10.1038/nature05249 (Pubitemid 44646176)
12. Folkman J., Figg W. D., Folkman J., History of angiogenesis. Angiogenesis: An Integrative Approach from Science to Medicine 2008 New York, NY, USA Springer 1 14
13. Chang J. H., Garg N. K., Lunde E., Han K. Y., Jain S., Azar D. T., Corneal neovascularization: an anti-VEGF therapy review. Survey of Ophthalmology 2012 57 5 415 429 10.1016/j.survophthal.2012.01.007
14. Cheng S., Dastjerdi M. H., Ferrari G., Okanobo A., Bower K. S., Ryan D. S., Stevenson W., Hamrah P., Nallasamy N., Dana R., Short-term topical bevacizumab in the treatment of stable corneal neovascularization. The American Journal of Ophthalmology 2012 154 6 940 958 10.1016/j.ajo.2012.06.007
15. Spaide R. F., Laud K., Fine H. F., Klancnik J. M. Jr., Meyerle C. B., Yannuzzi L. A., Sorenson J., Slakter J., Fisher Y. L., Cooney M. J., Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006 26 4 383 390 2-s2.0-33745091547 10.1097/00006982-200604000-00001 (Pubitemid 44197628)
16. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F. E., Paschke M., Zahn G., Cursiefen C., Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Investigative Ophthalmology and Visual Science 2007 48 6 2545 2552 2-s2.0-34247494559 10.1167/iovs.06-0570 (Pubitemid 351261204)
17. Papathanassious M., Theodoropoulou S., Analitis A., Tzonou A., Theodossiadis P. G., Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis. Cornea 2013 32 4 435 444 10.1097/ICO.0b013e3182542613
18. Doctor P. P., Bhat P. V., Foster C. S., Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008 27 9 992 995 2-s2.0-58149163501 10.1097/ICO.0b013e31817786ad
19. Gerten G., Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008 27 10 1195 1199 2-s2.0-60749105119 10.1097/ICO.0b013e318180e50f
20. Bock F., König Y., Kruse F., Baier M., Cursiefen C., Bevacizumab (avastin) eye drops inhibit corneal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 2 281 284 2-s2.0-38549107051 10.1007/s00417-007-0684-4 (Pubitemid 351149633)
21. Jae K., Dong K., Eun-Soon K., Myoung J. K., Hungwon T., Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovascularization. International Journal of Ophthalmology 2013 6 5 588 591
22. Kim S. W., Ha B. J., Kim E. K., Tchah H., Kim T. I., The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008 115 6 e33 e38 2-s2.0-44449119809 10.1016/j.ophtha.2008.02.013
23. Wu P. C., Kuo H. K., Tai M. H., Shin S. J., Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 2009 28 1 103 104 2-s2.0-62149145208 10.1097/ICO.0b013e3181822615
24. Carrasco M. A., Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008 27 6 743 745 2-s2.0-47949107165
25. Zheng M., Deshpande S., Lee S., Ferrara N., Rouse B. T., Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. Journal of Virology 2001 75 20 9828 9835 2-s2.0-0034815081 10.1128/JVI.75.20.9828-9835.2001 (Pubitemid 32900118)
26. Jin J., Guan M., Sima J., Gao G., Zhang M., Liu Z., Fant J., Ma J. X., Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003 22 5 473 477 2-s2.0-0038312077 10.1097/00003226-200307000-00015 (Pubitemid 36759043)
27. Uy H. S., Chan P. S., Ang R. E., Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 2008 27 1 70 73 2-s2.0-40449096035
28. Bahar I., Kaiserman I., McAllum P., Rootman D., Slomovic A., Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Current Eye Research 2008 33 1 23 28 2-s2.0-38549121685 10.1080/02713680701799101 (Pubitemid 351156952)
29. MacKenzie S. E., Tucker W. R., Poole T. R. G., Bevacizumab (avastin) for corneal neovascularization-corneal light shield soaked application. Cornea 2009 28 2 246 247 2-s2.0-67650585852 10.1097/ICO.0b013e3181861cc9
30. Yoeruek E., Ziemssen F., Henke-Fahle S., Tatar O., Tura A., Grisanti S., Bartz-Schmidt K. U., Szurman P., Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmologica 2008 86 3 322 328 2-s2.0-44649191186 10.1111/j.1600-0420.2007.01049.x (Pubitemid 351785106)
31. Yu C. Q., Zhang M., Matis K. I., Kim C., Rosenblatt M. I., Vascular endothelial growth factor mediates corneal nerve repair. Investigative Ophthalmology and Visual Science 2008 49 9 3870 3878 2-s2.0-53149126121 10.1167/iovs.07-1418
32. Jo N., Mailhos C., Ju M., Cheung E., Bradley J., Nishijima K., Robinson G. S., Adamis A. P., Shima D. T., Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. The American Journal of Pathology 2006 168 6 2036 2053 2-s2.0-33744728068 10.2353/ajpath.2006.050588 (Pubitemid 43825322)